/ 2 items

#FOLD↓

Featured/ FOLD/ 12/19/2025 · 8:10 AM

BioMarin to Acquire Amicus Therapeutics in $4.8 Billion Deal

BioMarin announces $4.8 billion acquisition of Amicus Therapeutics, adding rare disease treatments Galafold and Pombiliti to its portfolio with expected close in Q2 2026.

FOLD/ 09/18/2025 · 7:31 AM

Amicus Therapeutics: Why Analysts Are Bullish on FOLD Stock

Analysts Needham ($14 PT) & Morgan Stanley ($12 PT) are bullish on Amicus. Its DMX-200 drug for FSGS is de-risked by FDA changes, has huge sales potential ($1.5B+), and isn't yet priced into the stock. Both firms issued "Buy" ratings!